Exagen (XGN) Skyrockets 42% After Q3 Earnings Report
Exagen (XGN) , a medical diagnostic company, skyrocketed 42% the day after posting their Q3 earnings report. Exagen reported a quarterly loss of $0.47 per share versus the Zacks Consensus of a loss of $0.76 per share. Exagen also posted revenue of $14.73 million beating the Zacks Consensus Estimate by 61.24%.
“I’m very excited to be joining Exagen, as President and CEO,” said John Aballi. “Exagen has developed a leadership position in one of the largest fields of medicine with our proprietary AVISE testing platform. We are the Rheumatologist’s trusted partner in diagnostics, and I look forward to working with the team to continue to build on this foundation. Having spent the majority of my career working in labs, developing and commercializing diagnostics in oncology, I’m looking forward to bringing that same successful approach to Exagen.”
Exagen (Nasdaq: XGN) is a leading provider of autoimmune diagnostic, prognostic, and monitoring testing solutions. Exagen is a patient focused, discovery driven organization built on the success of AVISE testing and is investing in its product pipeline to support patients throughout their autoimmune diagnosis and treatment journeys. The goal at Exagen is to assist patients, physicians, and payors by enabling precision medicine. Exagen is located in San Diego County with clinical and research and development laboratories in Vista, CA.
For more information, please visit Exagen.com and follow @ExagenInc on Twitter.